Oncotelic Therapeutics Inc. (OTCQB: OTLC) is positioning its PDAOAI platform as a key player in the pharmaceutical industry’s broader shift toward artificial intelligence (AI)-integrated operations, according to a recent announcement. The platform, which indexes more than 125,000 PubMed abstracts on TGF-β signaling, enables researchers to interrogate evidence and generate testable, auditable hypotheses rather than relying on black-box predictive models.
Recent industry coverage has placed Oncotelic alongside companies such as Rockwell Automation, Emerson Electric, Thermo Fisher Scientific, and Danaher as contributors to the pharmaceutical sector’s move toward AI-enabled systems. The hypothesis-first approach of PDAOAI addresses a core challenge in biotech research: reducing training-set bias and building transparent, reproducible chains that link a question to evidence and then to a hypothesis.
Pharmaceutical research and manufacturing are undergoing a structural transition. Regulatory agencies are raising expectations around data integrity and traceability, while the industry is shifting from retrospective audits toward continuous, AI-enabled monitoring systems. At the same time, drug discovery is being reshaped by the growing availability of large-scale biomedical data and the tools to interrogate it at scale. Both shifts reflect a common underlying reality: manual processes and isolated datasets are no longer sufficient in an environment where scientific literature expands rapidly and regulatory expectations demand continuous, defensible documentation.
Oncotelic has responded to this environment with PDAOAI, an evidence-interrogation platform designed to surface testable research hypotheses from the global TGF-β literature. Instead of relying on traditional predictive models trained to replicate historical datasets, PDAOAI takes a retrieval-and-interrogation approach. The platform organizes and connects large volumes of biomedical literature, enabling researchers to identify patterns and generate testable hypotheses with direct links to the underlying evidence.
This approach is particularly relevant as the pharmaceutical industry increasingly adopts AI to improve efficiency and accuracy in drug discovery and manufacturing. However, concerns about the opacity of AI models have led to a push for more transparent and auditable systems. PDAOAI’s evidence-interrogation model directly addresses these concerns by ensuring that every hypothesis can be traced back to specific scientific papers and data points.
The implications of this technology extend beyond Oncotelic’s own research. By providing a tool that enhances reproducibility and reduces bias, PDAOAI could help accelerate the drug development process and improve the quality of scientific research across the industry. As regulatory scrutiny increases, the ability to demonstrate clear chains of evidence will become increasingly important for pharmaceutical companies seeking approval for new therapies.
For more information on Oncotelic Therapeutics and its latest developments, interested parties can visit the company’s newsroom at ibn.fm/OTLC.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oncotelic’s PDAOAI Platform Targets Pharma’s AI Transformation with Evidence-Interrogation Approach.